Leonard Johnson

The re-emergence of natural products for drug discovery in the genomics era

2012 and beyond: potential for the start of a second pre-antibiotic era?

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents

Antibiotics in the clinical pipeline in 2013

Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response

β-Lactams and β-Lactamase Inhibitors: An Overview

Discovery and resupply of pharmacologically active plant-derived natural products: A review

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009

LTX-109 Is a Novel Agent for Nasal Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus

Antibiotics and Bacterial Resistance in the 21st Century

The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies

Antibiotic Management of Methicillin-Resistant Staphylococcus aureus–Associated Acute Pulmonary Exacerbations in Cystic Fibrosis

Natural product and natural product derived drugs in clinical trials

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

Natural Products as Sources of New Drugs from 1981 to 2014

A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery

In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus

In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates